- Medicine Name: Odomzo
- API: Sonidegib
- Dosage Form & Strength: Capsules: 200 mg
- Manufactured By: Novartis
Odomzo (sonidegib) is a hedgehog pathway inhibitor used for the treatment of adults with locally advanced basal cell carcinoma (BCC) that has come back following surgery or radiation therapy, or those who are not the recipients for surgery or radiation therapy.
Recommended Dosage: The recommended dose of Odomzo is 200 mg administered orally once daily on an empty stomach, at least 1 hour before or 2 hours after a meal, administered until disease progression or unacceptable toxicity. Verify the pregnancy status of females of reproductive potential before starting therapy. Obtain serum creatine kinase (CK) levels and renal function tests before initiating this therapy in all patients. In case a dose of Odomzo is missed, resume dosing with the very next scheduled dose.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.